StockNews.AISignal intelligence
Alumis Inc. Common Stock · NASDAQ · Healthcare
Browse public ALMS signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Alumis disclosed topline ONWARD3 data for envudeucitinib, showing leading skin clearance in immune-mediated diseases. The update strengthens the program’s pipeline narrative and could prompt near-term catalysts, including potential partnerships or milestone timing, if additional data corroborates the topline results.
View signal analysisAlumis (ALMS) surged 107.9% after positive Phase 3 trial results. The drug envudeucitinib shows promise in treating plaque psoriasis. FDA application for envudeucitinib planned for 2026. Results enhance ALMS's competitiveness against Johnson & Johnson. Safety and significant outcomes strengthen investor confidence.
View signal analysisAlumis (ALMS) surged 107.9% post Phase 3 trial success. Envudeucitinib showed significant outcomes and safety for psoriasis treatment. FDA application planned for 2026 enhances market competitiveness against J&J.
View signal analysisAlumis stock surged 115.58% following ONWARD1 and ONWARD2 trial results. Envudeucitinib showed significant efficacy in treating plaque psoriasis. 74% of patients achieved PASI 75, indicating strong performance. Upcoming NDA submission expected in H2 2026 could drive further growth. ALMS is trading at a new 52-week high.
View signal analysisAlumis's experimental pill achieved main goals in two late-stage studies. Success in trials could significantly enhance ALMS's market position.
View signal analysisHC Wainwright initiates coverage on Alumis with a Buy rating. Alumis’ ESK-001 shows superior efficacy compared to competitors. Peak sales for ESK-001 projected at $1.9 billion in psoriasis. Sotyktu's patent expiration in 2026 could benefit ESK-001. ALMS is currently down 2.68% amid positive analyst expectations.
View signal analysis